Loading data for ENOV — first visit, this takes a few seconds.

알림

Enovis Corporation (ENOV)

NYSE: ENOV · 실시간 가격 · USD

26.17

-0.33 (-1.25%)

종가 기준: Aug 20, 2026, 6:50 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-1.25% (1D)

데이터 없음

매수호가	n/a
시가총액	1.51B
매출 (ttm)	2.3B
순이익 (ttm)	-1.1B
	1.45
	-19.27
	n/a
	6.52
P/B (ttm)	1.02
P/S (ttm)	0.66
실적 발표일	n/a

매도호가	n/a
거래량	271,590
평균 거래량 (20일)	1,190,303
시가	26.20
전일 종가	26.50
일중 범위	26.02 - 26.88
52주 범위	19.14 - 34.28
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ENOV 소개

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain mana...

[더 보기]

산업 Medical Devices

섹터 Healthcare

IPO 일자 May 8, 2008

직원 수 7,802

상장 거래소 NYSE

티커 ENOV

웹사이트 https://www.enovis.com

전체 기업 정보

재무 실적

2025년 Enovis의 매출은 2.25B로, 전년 2.11B 대비 6.66% 증가했습니다. 순이익은 -1.18B로, 43.48% 증가했습니다.

재무제표

어닝 서프라이즈

Enovis가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $582.78M 예상치 하회 $0, 및 3.23% 전년 대비 성장.

EPS 0.9 예상치 상회 0.05, 및 13.92% 전년 대비 성장.

뉴스

1주 전 · MarketBeat

Enovis Q2 Earnings Call Highlights

Enovis (NYSE:ENOV) reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Perfor...

2주 전 · GuruFocus.com

Enovis Corp (ENOV) (Q2 2026) Earnings Call Highlights: Strong Innovation Drives 5% Organic ...

Enovis Corp (ENOV) delivers solid Q2 2026 results with US recon growing 6% and Avis gaining traction, while navigating inflationary pressures and softer European markets.

2주 전 · Zacks

Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates

Enovis (ENOV) delivered earnings and revenue surprises of +8.43% and +0.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2주 전 · StockStory

Enovis (NYSE:ENOV) Posts Q2 CY2026 Sales In Line With Estimates

Medical technology company Enovis Corporation (NYSE:ENOV) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 3.2% year on year to $582.8 million. The company’s outlook for the full yea...

2주 전 · Zacks

Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates

Carlsmed, Inc. (CARL) delivered earnings and revenue surprises of +2.50% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 페이지 중 1

Enovis Corporation (ENOV)